Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2025-12-26 @ 1:59 AM
Study NCT ID:
NCT05873205
Status:
RECRUITING
Last Update Posted:
2025-07-29
First Post:
2023-05-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-21
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-29
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06-29
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-15
First Submit QC Date:
None
Study First Post Date:
2023-05-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-28
Last Update Post Date:
2025-07-29
Last Update Post Date Type:
ACTUAL